Evidence map›Paper›PMID 40150733›Full record

ArticleBioengineering (Basel, Switzerland)2025

Integrated Machine Learning Algorithms-Enhanced Predication for Cervical Cancer from Mass Spectrometry-Based Proteomics Data.

Da Zhang, Lihong Zhao, Bo Guo, Aihong Guo, Jiangbo Ding, Dongdong Tong, Bingju Wang, Zhangjian Zhou

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Da ZhangDepartment of Oncology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710000, China.ORCID 0000-0003-0037-6828
Lihong ZhaoDepartment of Dermatology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710000, China.ORCID 0000-0002-0385-7689
Bo GuoDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710000, China.ORCID 0000-0001-8986-5470
Aihong GuoDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710000, China.ORCID 0009-0000-2962-0818
Jiangbo DingDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710000, China.ORCID 0009-0006-0060-4279
Dongdong TongDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710000, China.
Bingju WangDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710000, China.ORCID 0009-0006-4752-5236
Zhangjian ZhouDepartment of Oncology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710000, China.

Funding

ACL HHS 90SF0018Key Research and Development Program of Shaanxi No.2024SF-YBXM-075Key Research and Development Program of Xianyang City No.L2024-ZDYF-ZDYF-SF-0018, L2023-ZDYF-SF-070, L2023-ZDYF-SF-069Medical Program of Jiangsu Provincial Health Commission No.MSZ2023081Science and Technology Program of Rugao City No.SRGS(23)095Young Talent Fund of Association for Science and Technology in Shaanxi No.20240323
6 · The paper itself

Abstract

Early diagnosis is critical for improving outcomes in cancer patients; however, the application of diagnostic markers derived from serum proteomic screening remains challenging. Artificial intelligence (AI), encompassing deep learning and machine learning (ML), has gained increasing prominence across various scientific disciplines. In this study, we utilized cervical cancer (CC) as a model to develop an AI-driven pipeline for the identification and validation of serum biomarkers for early cancer diagnosis, leveraging mass spectrometry-based proteomics data. By processing and normalizing serum polypeptide differential peaks from 240 patients, we employed eight distinct ML algorithms to classify and analyze these differential polypeptide peaks, subsequently constructing receiver operating characteristic (ROC) curves and confusion matrices. Key performance metrics, including accuracy, precision, recall, and F1 score, were systematically evaluated. Furthermore, by integrating feature importance values, Shapley values, and local interpretable model-agnostic explanation (LIME) values, we demonstrated that the diagnostic area under the curve (AUC) achieved by our multi-dimensional learning models approached 1, significantly outperforming the diagnostic AUC of single markers derived from the PRIDE database. These findings underscore the potential of proteomics-driven integrated machine learning as a robust strategy to enhance early cancer diagnosis, offering a promising avenue for clinical translation.

Indexed as

artificial intelligencecervical cancerearly diagnosisproteomics

Identifiers

PMID40150733
PMCPMC11939187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.